Clinical Trial

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

Study acronym: SPG50
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-14; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-17
Trial Details
NCT Number NCT06692712
Lead Sponsor Elpida Therapeutics SPC
Collaborators: University of Texas Southwestern Medical Center, Hospital Sant Joan de Deu
Conditions Hereditary Spastic Paraplegia Type 50
Enrollment 24 participants
Start Date 2026-04-01
Primary Completion 2032-02-28 (estimated)
Study Completion 2032-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20